title: Estradiol reduces susceptibility of CD4+ T cells and macrophages to HIV-infection.
abstract: The magnitude of the HIV epidemic in women requires urgent efforts to find effective preventive methods. Even though sex hormones have been described to influence HIV infection in epidemiological studies and regulate different immune responses that may affect HIV infection, the direct role that female sex hormones play in altering the susceptibility of target cells to HIV-infection is largely unknown. Here we evaluated the direct effect of 17-β-estradiol (E2) and ethinyl estradiol (EE) in HIV-infection of CD4(+) T-cells and macrophages. Purified CD4(+) T-cells and monocyte-derived macrophages were generated in vitro from peripheral blood and infected with R5 and X4 viruses. Treatment of CD4(+) T-cells and macrophages with E2 prior to viral challenge reduced their susceptibility to HIV infection in a dose-dependent manner. Addition of E2 2 h after viral challenge however did not result in reduced infection. In contrast, EE reduced infection in macrophages to a lesser extent than E2 and had no effect on CD4(+) T-cell infection. Reduction of HIV-infection induced by E2 in CD4(+) T-cells was not due to CCR5 down-regulation, but was an entry-mediated mechanism since infection with VSV-G pseudotyped HIV was not modified by E2. In macrophages, despite the lack of an effect of E2 on CCR5 expression, E2-treatment reduced viral entry 2 h after challenge and increased MIP-1β secretion. These results demonstrate the direct effect of E2 on susceptibility of HIV-target cells to infection and indicate that inhibition of target cell infection involves cell-entry related mechanisms.
authors.affiliation: Department of Physiology and Neurobiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America. Marta.Rodriguez.Garcia@dartmouth.edu
authors.forename: Marta
authors.initials: M
authors.lastname: Rodriguez-Garcia
authors.forename: Nabanita
authors.initials: N
authors.lastname: Biswas
authors.forename: Mickey V
authors.initials: MV
authors.lastname: Patel
authors.forename: Fiona D
authors.initials: FD
authors.lastname: Barr
authors.forename: Sarah G
authors.initials: SG
authors.lastname: Crist
authors.forename: Christina
authors.initials: C
authors.lastname: Ochsenbauer
authors.forename: John V
authors.initials: JV
authors.lastname: Fahey
authors.forename: Charles R
authors.initials: CR
authors.lastname: Wira
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology*; D004198:Disease Susceptibility / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology* / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D008024:Ligands; D008264:Macrophages / Q000187:drug effects / Q000821:virology*; D019713:Receptors, CCR5 / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D053586:Virus Internalization / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
chemical_list: D008024:Ligands; D019713:Receptors, CCR5; D011960:Receptors, Estrogen; D004997:Ethinyl Estradiol; D004958:Estradiol